Using CRISPR gene editing, a team from Children’s Hospital of Philadelphia (CHOP) and Penn Medicine have thwarted a lethal lung disease in an animal model in which a harmful mutation causes death within hours after birth.
This proof-of-concept study, published today in Science Translational Medicine, showed that in uteroediting could be a promising new approach for treating lung diseases before birth.
“The developing fetus has many innate properties that make it an attractive recipient for therapeutic gene editing,” said study co-leader William H. Peranteau, MD, an investigator at CHOP’s Center for Fetal Research, and a pediatric and fetal surgeon in CHOP’s Center for Fetal Diagnosis and Treatment. “Furthermore, the ability to cure or mitigate a disease via gene editing in mid- to late gestation before birth and the onset of irreversible pathology is very exciting. This is particularly true for diseases that affect the lungs, whose function becomes dramatically more important at the time of birth.”
The lung conditions the team is hoping to solve — congenital diseases such as surfactant protein deficiency, cystic fibrosis, and alpha-1 antitrypsin — are characterized by respiratory failure at birth or chronic lung disease with few options for therapies. About 22 percent of all pediatric hospital admissions are because of respiratory disorders, and congenital causes of respiratory diseases are often lethal, despite advances in care and a deeper understanding of their molecular causes. Because the lung is a barrier organ in direct contact with the outside environment, targeted delivery to correct defective genes is an attractive therapy.
“We wanted to know if this could work at all,” said study co-leader Edward E. Morrisey, PhD, a professor of Cardiovascular Medicine in the Perelman School of Medicine at the University of Pennsylvania. “The trick was how to direct the gene-editing machinery to target cells that line the airways of the lungs.”
The researchers showed that precisely timed in utero delivery of CRISPR gene-editing reagents to the amniotic fluid during fetal development resulted in targeted changes in the lungs of mice. They introduced the gene editors into developing mice four days before birth, which is analogous to the third trimester in humans.
The cells that showed the highest percentage of editing were alveolar epithelial cells and airway secretory cells lining lung airways. In 2018, a team led by Morrisey identified the alveolar epithelial progenitor (AEP) lineage, which is embedded in a larger population of cells called alveolar type 2 cells. These cells generate pulmonary surfactant, which reduces surface tension in the lungs and keeps them from collapsing with every breath. AEPs are a stable cell type in the lung and turn over very slowly, but replicate rapidly after injury to regenerate the lining of the alveoli and restore gas exchange.
In a second experiment, the researchers used prenatal gene editing to reduce the severity of an interstitial lung disease, surfactant protein C (SFTPC) deficiency, in a mouse model that has a common disease-causing mutation found in the human SFTPC gene. One hundred percent of untreated mice with this mutation die from respiratory failure within hours of birth. In contrast, prenatal gene editing to inactivate the mutant Sftpc gene resulted in improved lung morphology and survival of over 22 percent of the animals.
Future studies will be directed toward increasing the efficiency of the gene editing in the epithelial lining of lungs as well as evaluating different mechanisms to deliver gene editing technology to lungs. “Different gene editing techniques are also being explored that may one day be able to correct the exact mutations observed in genetic lung diseases in infants,” Morrisey said.
Learn more: Researchers Use Gene Editing with CRISPR to Treat Lethal Lung Diseases before Birth
The Latest on: Gene editing
[google_news title=”” keyword=”gene editing” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Gene editing
- Moderna ends collaboration with CRISPR company Metagenomi, parts ways with gene editing chiefon May 1, 2024 at 1:03 pm
Moderna invested part of its vaccine windfall into a new gene-editing startup, Metagenomi. Now it's backing out.
- Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systemson May 1, 2024 at 1:00 pm
Enhances strategic flexibility and control of key gene editing technologies and programsEMERYVILLE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MGX), a precision genetic medicines company ...
- Moderna exits gene editing deal worth up to $3B biobucks, leaving Metagenomi in the spotlighton May 1, 2024 at 1:00 pm
Earlier this year, Metagenomi had the spotlight with a $93.7 million IPO. Now, Moderna is exiting stage left on a partnership worth up to $3 billion in biobucks.
- Invest In A Revolutionary Gene Therapy With CRISPR Therapeuticson April 30, 2024 at 10:25 am
CRISPR Therapeutics' Casgevy could generate significant shareholder value if proven to be successful. Learn why I am highly bullish on CRSP stock.
- Prime Medicine Gets FDA Okay for First Trial of Gene Editing Techniqueon April 30, 2024 at 8:27 am
The FDA has cleared a clinical trial of an ex vivo prime editing candidate in patients with a rare disease, Prime Medicine announced Monday. The technique taps CRISPR technology to rewrite defective ...
- Boosting crop colors with gene editing can improve weed controlon April 30, 2024 at 1:53 am
At the heart of this progressive strategy lies the concept of modifying the composition of crops with gene editing ...
- Gene seekers discover atypical genes that control multiple valuable soybean traitson April 30, 2024 at 1:27 am
A team led by Purdue University soybean geneticist Jianxin Ma has developed a new biotechnological tool for the domestication of desirable traits from wild soybeans, such as resistance to leafhopper ...
- CRISPR-Cas Gene Editing Help Combat Antimicrobial Resistanceon April 29, 2024 at 11:08 am
Despite rising global antimicrobial resistance (AMR), researchers highlight CRISPR/Cas systems' potential in antimicrobial agent development.
- Generative AI arrives in the gene editing world of CRISPRon April 29, 2024 at 6:00 am
Much like ChatGPT generates poetry, a new AI system devises blueprints for microscopic mechanisms that can edit your DNA.
- ‘ChatGPT for CRISPR’ creates new gene-editing toolson April 28, 2024 at 5:00 pm
This week, researchers published details of how they used a generative AI tool called a protein language model — a neural network trained on millions of protein sequences — to design CRISPR ...
via Bing News